Medicare AdvantageCoverageHigh impact
[Georgia] Carelon Medical Benefits Management Clinical Appropriateness Guidelines updates
Anthem BCBS·GA · Oncology, Genetics, Orthopedics +1 more·Provider Bulletin
Effective date
Nov 15, 2026
We identified it
Aug 2, 2026
Summary
Carelon Medical Benefits Management updated clinical appropriateness guidelines for genetic testing, somatic tumor testing, and musculoskeletal procedures effective November 15, 2026. Key changes include expanded indications for molecular testing in multiple cancer types (breast, prostate, thyroid, colorectal, lung), new drug therapies triggering testing requirements (imlunestrant, niraparib), standardized 12-week conservative management requirements for joint surgery, and clarification of non-covered services like whole exome/genome sequencing and certain liquid biopsy applications.
Action Required
By November 15, 2026: (1) Billing and Prior Authorization Teams: Review and update all genetic testing and somatic tumor testing prior authorization criteria in the billing system to reflect expanded indications for breast cancer (stages IIB, IIIA, IIIB, IIIC), prostate cancer (all metastatic indications), thyroid cancer, colorectal cancer (PIK3CA testing), and lung cancer rebiopsy scenarios. (2) Update criteria to recognize new drug therapies: imlunestrant for breast cancer ESR1 testing and niraparib for prostate cancer testing. (3) Orthopedic/Surgical Billing Teams: Implement standardized 12-week conservative management documentation requirements across all joint surgery procedures (shoulder, hip, knee arthroplasty/arthroscopy). Update pre-authorization templates to require 12-week pre-procedure interval from arthroscopy to arthroplasty. (4) Claims Processing: Configure system denials for non-covered services including WES, WGS, WTA, RNA fusion/expression/transcriptome analysis using ctRNA, and thyroid NIFTP somatic testing. (5) Provider Education: Distribute updated guidelines to oncology, orthopedic, and surgical providers to ensure compliant ordering and documentation. Failure to implement these changes will result in claim denials for services not meeting updated medical necessity criteria and potential overpayments for services now deemed not medically necessary.